|
Nathaniel E. David, PhD | Chief Science Officer, Kythera
Nathaniel "Ned" David, PhD, co-founder and Chief Science Officer of Kythera, looks for unexpected ways to take biological insights and marry them with unmet needs in aesthetic medicine. As the co-founder of Syrrx (acquired by Takeda for $270 million in 2005) and Achaogen, he has experience creating and growing innovative biotechnology companies. Ned was named one of the Top 100 innovators in the world under 35 (2002) by the MIT Technology Review.
Ned holds numerous pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, energy production, and aesthetic medicine. He sits on the board of trustees of the UC Foundation and on the board of directors of Sapphire Energy, a next-generation bioenergy company producing liquid transportation fuels that are 100% compatible with the existing energy infrastructure. He holds a PhD from UC Berkeley in Molecular and Cellular Biology and an AB in Biology from Harvard College.
|
Dennis Fenton, PhD
As immediate past Executive Vice President of Operations at Amgen, Inc., Dennis was responsible for worldwide operations, manufacturing, process development and quality. A true pioneer in biotechnology, he left Pfizer 25 years ago to join the promising start-up company Amgen. Since that time Dennis has held numerous executive leadership roles at Amgen including operations, and sales and marketing. Dennis also serves on the board of directors of the Biotechnology Industry Organization (BIO), the board of trustees of the Keck Graduate Institute, and the board of regents of California Lutheran University. He has a PhD in Microbiology from Rutgers University.
|
|
|
Hironori Hozoji | Investment Officer, JAFCO Life Science Investment
Hironori Hozoji is a seasoned venture capitalist with sixteen years of experience at JAFCO Co., Ltd. in Tokyo, Japan and six years of experience at JAFCO Life Science Investment in San Diego, CA. Hironori has led more than 49 investments totaling over $185 million in the US, Europe and Asia Pacific. He has led private investments for and/or served on the board of directors of numerous public and private companies including Affymax, Artisan Pharma, Inc., Agensys, Lipocyte Pharmaceuticals, among others. Hironori holds a BA in Business Administration from Meiji University in Tokyo, Japan. For more information visit http://www.jafco.co.jp/eng/home/index.html
|
Keith Leonard | President and Chief Executive Officer, Kythera
Keith Leonard, a co-founder of Kythera, and President and Chief Executive Officer, is directing the newly formed management team and leveraging the experience of the board of directors.
Formerly, as Senior Vice president and General Manager of Amgen Europe, Keith was responsible for all commercial operations in 28 countries. During his tenure in Europe he built a team that took the company’s products to market leadership in oncology and nephrology, and dramatically expanded the company’s operations, in just three years. Prior to that experience, his career at Amgen included establishing Amgen’s presence in rheumatology with the creation of the Rheumatology Business Unit, Head of Information Management, and leadership roles in Sales and Marketing, Engineering, Operations, and Finance. Keith is also a board member of ARYx Therapeutics.
Keith holds a BS in Engineering from the University of California, Los Angeles (UCLA); a BA in History from the University of Maryland; an MS in Engineering from the University of California, Berkeley; and an MBA from the Anderson School of Management at UCLA.
|
|
|
Robert T. Nelsen | Managing Director, ARCH Venture Partners
Bob joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies. He is a director of Adolor, Elixir, Ensemble Discovery, NeurogesX, and Ikaria, among others. Bob also serves on the board of Fred Hutchinson Cancer Research Institute. Bob holds an MBA from the University of Chicago and a BS in both Economics and Biology from the University of Puget Sound. For more information visit http://www.archventure.com.
|
Camille Samuels | Managing Director, Versant Ventures
Camille specializes in biotechnology investing at Versant. She joined Versant in early 2000, shortly after its formation. Prior to her experience at Versant, Camille was responsible for business development at Tularik, Inc. (subsequently acquired by Amgen) where she in-licensed two of the company's clinical-stage products and led Tularik's Technology Acquisition Group. Before Tularik, Camille worked in business development/strategic planning at Genzyme and Millennium Predictive Medicine, and as a management consultant to healthcare and biotech companies at LEK Consulting. Camille earned her BS in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow. For more information visit http://www.versantventures.com.
|
|
|
David Schnell, MD | Managing Director, Prospect Venture Partners
Prospect Venture Partners is a dedicated life science venture capital firm with over $1 billion of capital under management. David has led private investments for and/or served on the board of directors of numerous public and private companies including Gloucester Pharmaceuticals, Healtheon, Microcide Pharmaceuticals, Neurocrine Biosciences, Rinat Neuroscience, Senomyx, Somaxon Pharmaceuticals, Trine, and Trubion Pharmaceuticals. David received an MD from Harvard Medical School, an MA in Health Services Research from Stanford University School of Medicine, and a BS in Biological Sciences from Stanford University. For more information visit http://www.prospectventures.com.
|
Joseph Turner
Joseph Turner joins Kythera’s Board with more than 25 years of financial management experience in pharmaceutical and biotech industries worldwide. As Chief Financial Officer of several early stage industrial companies, Turner was responsible for eight equity offerings, including three Initial Public Offerings (IPOs), raising a total of $450 million in the public and private markets. He spent seven years as Chief Financial Officer at Myogen, Inc. where he led two private and three public rounds of financing and was a key player in the negotiation of the $2.5 billion sale of the company to Gilead Sciences in 2006. Prior to Myogen, Turner was Vice President of Finance at Cortech, Inc. where he led the transition from a private concern to a public company and successfully completed both IPO and follow-on offerings. Other financial leadership roles include Director of Finance, Eli Lilly and Company (Switzerland); Treasurer, Eli Lilly and Company (Switzerland); and Vice President of Finance, Centaur Pharmaceuticals. He is member of the Board of Directors of Sequel Pharmaceuticals and of SGX Pharmaceuticals and is a former board member and Chairman of the Audit Committee of NovaCardia, Inc.
Turner holds a BA in Chemistry from Swarthmore College; an MA in Molecular Biology from the University of Colorado at Boulder; and an MBA from University of North Carolina at Chapel Hill.
|
|
|
